Page 36 | Certara

On-Demand Webinar

Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions

Vice President and Head of Global PK/PD and Pharmacometrics at Eli Lilly and Company Dr.…

CertaraJanuary 29, 2025

White Paper

The Benefits of Real-Time Nonclinical Safety Data Analysis

Learn how SEND Explorer software helps nonclinical drug developers streamline performing real-time toxicology assessments of…

CertaraJanuary 27, 2025

Publication

Understanding Variability in CAR-T Cell Therapy Kinetics

Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…

CertaraJanuary 23, 2025

Announcement

Certara Awarded European Medicines Agency Project to Assess Real-World Data Landscape for CAR-T Cell Therapies

January 22, 2025 Radnor, PA – January 22, 2025 – Certara, Inc. (Nasdaq: CERT), a…

CertaraJanuary 22, 2025

Publication

Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses

This Frontiers in Pharmacology article investigates how using different time-averaged exposure metrics, specifically the time-averaged…

CertaraJanuary 21, 2025

Live Events

Model-Informed Drug Development: Current Landscape and Future Directions

Date: Tuesday, February 25, 2025Time: 5:30 - 8:00pmVenue: CIC Cambridge - One Broadway, Cambridge, MA…

CertaraJanuary 17, 2025

Blog

Anonymization vs. Redaction of Clinical Trial Data

January 17, 2025 The vernacular for disclosing pharmaceutical clinical trial results to the public may…

CertaraJanuary 17, 2025

Publication

Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals

Background Coronavirus disease 2019 (COVID-19) remains a major public health concern, with continued resurgences of…

CertaraJanuary 16, 2025

Poster

Dose Guidance for a Novel Combination Therapy to Treat Head and Neck Squamous Cell Carcinoma (HNSCC) for Patients with HRAS/PIK3CA Variants Using a Quantitative Systems Pharmacology (QSP) Model

CertaraJanuary 16, 2025

Press Release

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

January 15, 2025 Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted…

CertaraJanuary 15, 2025

Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions

The Benefits of Real-Time Nonclinical Safety Data Analysis

Understanding Variability in CAR-T Cell Therapy Kinetics

Certara Awarded European Medicines Agency Project to Assess Real-World Data Landscape for CAR-T Cell Therapies

Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses

Model-Informed Drug Development: Current Landscape and Future Directions

Anonymization vs. Redaction of Clinical Trial Data

Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals

Dose Guidance for a Novel Combination Therapy to Treat Head and Neck Squamous Cell Carcinoma (HNSCC) for Patients with HRAS/PIK3CA Variants Using a Quantitative Systems Pharmacology (QSP) Model

Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Newsletter sign up

Quick links

Solutions

Contact